What's in Dr.Vandana Bansal's pipeline?

Dr.Vandana Bansal has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Dr.Vandana Bansal's portfolio?

Top competitors by shared drug class: Shiraz University of Medical Sciences.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dr-vandana-bansal.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Dr.Vandana Bansal — Portfolio Competitive Intelligence Brief

Dr.Vandana Bansal pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Heparin & aspirin	Heparin & aspirin	phase 3	Anticoagulant and antiplatelet combination	Thrombin, Factor Xa, COX-1	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Shiraz University of Medical Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dr.Vandana Bansal:

Cite this brief

Drug Landscape (2026). Dr.Vandana Bansal — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dr-vandana-bansal. Accessed 2026-05-16.